GlassScriptPhysician profile
Mariana Varga
NPI 1962542225
$183,493.32
in general payments reported to CMS, 2019-2025
33 companies · $21K in 2025
The $21K reported for 2025 was more than what 93% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $59K · 2020: $24K · 2021: $40K · 2022: $20K · 2023: $14K · 2024: $5,541 · 2025: $21K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Honoraria: $17K · Food and Beverage: $9,450 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $7,700 · Travel and Lodging: $4,318 · Consulting Fee: $2,560.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Honoraria | $16,580.00 |
| Food and Beverage | $9,449.82 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $7,700.00 |
| Travel and Lodging | $4,317.79 |
| Consulting Fee | $2,560.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mdd US Operations, LLC | $47,169.15 | 2019-2025 | Gocovri, Gocovri |
| Neurocrine Biosciences, INC. | $26,595.69 | 2019-2025 | Ongentys, Ingrezza |
| Adamas Pharmaceuticals, INC. | $18,196.96 | 2019-2021 | |
| Teva Pharmaceuticals USA, INC. | $16,514.88 | 2019-2025 | Austedo Xr, Austedo Xr, Austedo |
| Acorda Therapeutics, INC | $16,142.24 | 2019-2024 | Inbrija |
| Abbott Laboratories | $15,885.85 | 2019-2025 | Infinity |
| Lundbeck LLC | $11,084.88 | 2019-2021 | |
| Medtronic, INC. | $9,498.23 | 2021-2025 | Percept PC Brainsense, Sensight, Nexframe |
| Amneal Pharmaceuticals LLC | $7,806.30 | 2019-2025 | Rytary, Crexont, Ongentys 50mg Capsules 30 |
| Sunovion Pharmaceuticals INC. | $3,505.59 | 2020-2022 | |
| Boston Scientific Corporation | $2,936.86 | 2020-2025 | Vercise, General - Dbs |
| Medtronic USA, INC. | $2,088.46 | 2019-2020 | |
| Acadia Pharmaceuticals INC | $1,628.31 | 2019-2025 | Nuplazid, Daybue |
| Sage Therapeutics, LLC | $1,041.54 | 2023 | |
| Ucb, INC. | $768.73 | 2019 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $633.68 | 2022-2025 | Duopa, Botox |
| Kyowa Kirin, INC. | $428.72 | 2019-2023 | Nourianz |
| Merz North America, INC. | $221.42 | 2019-2020 | |
| Biogen, INC. | $177.06 | 2021-2025 | Skyclarys |
| Microtransponder, INC. | $157.35 | 2025 | |
| Avion Pharmaceuticals | $152.38 | 2022-2023 | Dhivy |
| Merz Pharmaceuticals, LLC | $125.75 | 2021-2024 | Xeomin |
| Ipsen Biopharmaceuticals, INC | $119.79 | 2019-2023 | Dysport |
| Argenx US, INC. | $116.38 | 2025 | Vyvgart |
| Allergan, INC. | $102.80 | 2019-2020 | |
| Eisai INC. | $95.71 | 2021-2022 | |
| Ge Healthcare | $89.14 | 2019-2023 | |
| Arbor Pharmaceuticals, INC. | $85.82 | 2019-2021 | |
| Supernus Pharmaceuticals, INC. | $51.33 | 2023-2025 | Qelbree |
| Vertical Pharmaceuticals, LLC | $36.94 | 2019 | |
| Insightec,INC | $20.73 | 2022 | |
| Azurity Pharmaceuticals, INC. | $14.65 | 2023 | Horizant |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mariana Varga listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.